Monteriggioni, 8 October - DIESSE's commitment in the fight against the pandemic continues, offering new and effective support in identifying patients’ state of health. DIESSE’s newly developed serological test, which detects SARS-CoV-2 virus antibodies (IgG, IgM and IgA) through an automated method on the Chorus platform, has sensitivity and specificity values higher than 99%. Furthermore, the sensitivity of the test is already very high (97%) in the 0-6 day window from the onset of symptoms, providing a valid aid in the early serological diagnosis of COVID 19. This new kit is an ideal complement to molecular tests, allowing early detection of patients’ immune response to the virus.
“This latest achievement, made possible due to the commitment and determination of the DIESSE researchers, increases the portfolio of diagnostic tests offered by our company to counter the COVID pandemic”, says Luigi Nava, Commercial Operations Director. “Thanks to this new dosage, DIESSE can make a new high-performance diagnostic test for monitoring patients' immune responses. The new test could also be used to check the immune status of vaccinated people, something which we hope can happen in the near future”.